Active substanceAmphotericin BAmphotericin B
Similar drugsTo uncover
  • Ambiz®
    powder d / infusion 
  • Amphotericin B
    lyophilizate d / infusion 
    SYNTHESIS, OJSC     Russia
  • Dosage form: & nbsplyophilizate for solution for infusion
    Composition:

    Active substance: Amphotericin B (in terms of active substance) - 50,000 μg (ED).

    Excipients: sodium hydrogen phosphate dodecahydrate (sodium phosphate disubstituted 12-water), sodium dihydrogen phosphate dihydrate (sodium phosphate monosubstituted 2-water), sodium deoxycholate: sodium hydroxide, deoxycholic acid.

    Description:A porous mass of yellow color.
    Pharmacotherapeutic group:Antifungal agent
    ATX: & nbsp

    J.02.A.A.01   Amphotericin B

    Pharmacodynamics:

    Polyene macrocyclic antibiotic with antifungal activity. Streptomyces nodosus is produced. It has a fungicidal or fungistatic effect depending on the concentration in biological fluids and the sensitivity of the pathogen. It binds to sterols (ergosterols) located in the cell membrane of a fungus that is sensitive to the drug. As a result, the permeability of the membrane is violated and the intracellular components exit into the extracellular space and lysis of the fungus.

    It is active against most strains of Histoplasma capsulatum, Coccidioides immitis, Paracoccidioides braziliensis, Candida spp., Blastomyces dermatidis, Rhodotorula spp., Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, Rhizopus spp., Absidia spp., Basodiobolus ranarum, Aspergillus fumigatus.

    Moderately active against some protozoa: Leishmania braziliensis, Leishmania mexicana, Naegleria fowleri.

    Amphotericin B is generally stable: Pseudallescheria boydii, Fusarium spp.

    Ineffective against bacteria, rickettsia, viruses.

    Pharmacokinetics:

    After a single intravenous injection, an effective concentration (dose-dependent) is created in the blood, which lasts for 24 hours. After intravenous administration of 1-5 mg / day, the maximum concentration (Cmax) in plasma is 0.5-2 μg / ml. The connection with plasma proteins is more than 90%. It is distributed in the lungs, liver, spleen, kidneys, adrenal glands, muscles and other tissues. Concentrations in pleural effusion, peritoneal, synovial fluids, aqueous humor reach about 2/3 of the concentration in the plasma; in-the cerebrospinal fluid is usually not determined. The apparent volume of distribution in adults is 4 l / kg, in children 0.4-8.3 l / kg, in newborns 1.5-9.4 l / kg.

    Metabolized (ways are unknown). In bile and urine, about 98% is present in the form of metabolites. It is excreted slowly by the kidneys, the half-life of the initial in adults is 24 hours, children - 5.5-40.3 hours, in newborns - 18.8-62.5 hours; the elimination half-life is final -15 days. Despite the delayed excretion, cumulates weakly. It is not practically eliminated during hemodialysis.After cancellation is detected in the body for several more weeks.

    Indications:

    Progressing, life-threatening fungal infections caused by amphotericin-sensitive B microorganisms: disseminated cryptococcosis, cryptococcal meningitis; meningitis caused by other fungi, invasive and disseminated aspergillosis, North American blastomycosis, disseminated forms of candidiasis, coccidioidosis, paracoccidioidosis, histoplasmosis, ficomycosis (zygomycosis), chromomycosis, moldy mycosis, disseminated sporotrichosis, hyalogomycosis, chronic mycetoma, abdominal infections (including peritonitis), endocarditis, endophthalmitis, fungal sepsis, fungal infections of the urinary tract.

    Visceral leishmaniasis (including in patients with immunodeficiency), American skin-visceral leishmaniasis (not a drug of choice).

    Contraindications:Hypersensitivity, chronic renal failure, lactation.
    Carefully:Kidney diseases (including glomerulonephritis), amyloidosis, hepatitis, liver cirrhosis, anemia, agranulocytosis, diabetes mellitus, pregnancy.
    Dosing and Administration:

    Intravenously drip for 2-4 hours, the recommended concentration is 0.1 mg / ml.

    Trial dose - 1 mg (base) is diluted in 20 ml of 5% dextrose solution and administered intravenously for at least 20-30 minutes under the control of blood pressure, pulse, body temperature every 30 minutes for 2-4 hours.

    With good tolerability, the recommended daily dose is 0.25-0.3 mg / kg, depending on the severity of the disease.

    With increased sensitivity to the drug, diseases of the cardiovascular system, kidney failure, treatment starts with low doses of 5-10 mg and, gradually increasing by 5-10 mg / day, adjusted to the recommended daily dose of 0.5-0.7 mg / kg.

    Selection of therapeutic doses is carried out individually, depending on the type and severity of the infection. When using the drug every other day, the dose should not exceed 1.5 mg / kg (to avoid the development of cardiopulmonary insufficiency).

    The maximum daily dose is 1.5 mg / kg.

    Sporotrichosis: course dose 2.5 g, duration of therapy - 9 months.

    Aspergillosis: course dose - 3.6 g, treatment duration - 11 months.

    Rhinocerebral fikomycosis: the course dose is 3-4 g.

    In the event of discontinuation of therapy for more than 7 days, it should be resumed at the lowest dose (0.25 mg / kg), gradually increasing to the desired level.

    Children: intravenously, first 0.25 mg / kg (base) per day in a 5% dextrose solution for 6 hours; taking into account tolerability, the dose is gradually increased (usually 0.125 - 0.25 mg / kg every day or every other day) to a maximum dose of 1 mg / kg or 30 mg per 1 m2.

    Children are given minimal effective doses.

    To prepare a solution for intravenous administration, a solution with an initial concentration of 5 mg / ml is used. To do this, sterile syringe (needle no. 20) -contain 10 ml of sterile water for injection without bacteriostatic additives directly into the vial with the drug. The contents of the vial are shaken to form a clear colloidal solution. To obtain a solution with a concentration of 0.1 mg / ml it is diluted with 5% dextrose solution with pH not lower than 4.2 in a ratio of 1:50. Before dilution it is necessary to check the acidity of the available dextrose solution. The pH of the dextrose solution generally exceeds 4.2, otherwise 1-2 ml of the buffer solution should be added to the dilution.

    The following buffer solution is recommended: sodium hydrophosphate (anhydrous) - 1.59 g, sodium dihydrogen phosphate (anhydrous) - 0.96 g, water for injection - up to 100 ml.

    Before addition to the dextrose solution, the buffer solution is sterilized by filtration through a bacterial ceramic ormembrane filter or by autoclaving for 30 minutes at a pressure of 1 atm and 121 ° C.

    Side effects:

    From the digestive system: often - decreased appetite, dyspepsia, nausea, vomiting, diarrhea, gastralgia, hepatotoxicity (increased activity of "liver" enzymes, hyperbilirubinemia); infrequently - acute hepatic insufficiency, hepatitis, jaundice, hemorrhagic gastroenteritis, melena.

    From the nervous system: often - a headache, infrequently - cramps, transient vertego, peripheral neuropathy, encephalopathy.

    From the sense organs: infrequently - impaired vision, diplopia; loss of hearing, tinnitus.

    From the hematopoiesis: often - normochromic normocytic anemia; infrequently - agranulocytosis, blood clotting disorder, leukopenia, hemolytic anemia, thrombocytopenia, eosinophilia, leukocytosis.

    From the cardiovascular system: often - lowering blood pressure; infrequent - arrhythmias, including ventricular fibrillation, changes in the ECG, increased blood pressure, shock, cardiac arrest, heart failure.

    From the respiratory system: often - tachypnea; infrequently - shortness of breath, allergic pneumonitis, pulmonary edema.

    From the urinary system: often - renal dysfunction, including azotemia, hypokalemia, hyposthenia, renal tubular acidosis, nephrocalcinosis; infrequently - acute renal failure, oliguria, anuria, nephrogenic diabetes insipidus. Preliminary introduction of 0.9% sodium chloride solution reduces the risk of nephrotoxicity, the introduction of sodium bicarbonate - the risk of renal tubular necrosis.

    Allergic reactions: often - anaphylactoid reactions, bronchospasm, sneezing; infrequent - rash, especially maculopapular, itching, exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome.

    Local reactions: thrombophlebitis at the injection site, chemical burn.

    Other: often - fever, weight loss, myalgia, arthralgia, general weakness.

    Laboratory indicators: hypokalemia, hyperkalemia, hypomagnesemia, hypocalcemia, hypercreatininaemia.

    Overdose:

    Symptoms: cardiac and respiratory arrest.

    Treatment: symptomatic. It is necessary to monitor cardiac and respiratory activity, liver and kidney function,pictures peripheral. blood and electrolyte content and prescribe maintenance therapy. It is not removed during hemodialysis.

    Before the resumption of treatment, the patient's condition should be stabilized.

    Interaction:

    Pharmaceutically incompatible with heparin, 0.9% sodium chloride solution and other solutions containing electrolytes.

    The presence of bacteriostatic additives (including benzyl alcohol) can lead to precipitation of the drug.

    Synergy with nitrofurans.

    Increases the effect and toxicity of anti coagulants, theophylline and sulfonylureas, flucytosine (prolongs half-life); reduces the effect of ethinyl estradiol - the risk of bleeding "breakthrough".

    Inhibitors of microsomal liver enzymes (incl. cimetidine, non-narcotic analgesics, antidepressants) slow down metabolic rate, increase serum concentration (increase in toxicity).

    Inductors of microsomal liver enzymes (including phenytoin, rifampicin, barbiturates, carbamazepine) accelerate metabolism in the liver (decreased effect).

    Increases the toxic effect of cardiac glycosides (especially against the background of the initial deficiency of potassium in the body) and curare-like muscle relaxants.

    Glucocorticosteroids, carbonic anhydrase inhibitors, adrenocorticotropic hormones increase the risk of hypokalemia.

    It is not possible to appoint simultaneously with nephrotoxic drugs (aminoglycosides, ciclosporin, pentamidine and others) - the risk of kidney dysfunction increases.

    Antineoplastic drugs, radiation therapy and drugs that inhibit bone marrow hematopoies increase the risk of anemia and other hematologic disorders.

    Antitumor drugs increase nephrotoxicity, bronchospasm and lower blood pressure.

    Glucocorticosteroids and corticotropin increase hypokalemia, which can lead to the development of arrhythmias. If it is necessary to prescribe these medicines at the same time, electrolyte blood composition and ECG should be monitored.

    Amphotericin B may increase the toxicity of cardiac glycosides (due to hypokalemia).

    Simultaneous administration with imidazoles (including fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole) can lead to the development of resistance to amphotericin B.Combined treatment with imidazoles with amphotericin B should be administered with caution.

    It is not possible to appoint simultaneously with nephrotoxic drugs (aminoglycosides, ciclosporin, pentamidine and others) - the risk of kidney dysfunction increases.

    Lengthens the muscle relaxant effect of depolarizing muscle relaxants.

    Leukocyte mass should be administered at a significant interval after the administration of amphotericin B (the risk of complications from the respiratory system).

    Special instructions:

    Amphotericin B should be used primarily for the treatment of progressive and life-threatening fungal infections. It should not be used to treat noninvasive (superficial) mycoses, such as candidiasis of the oral cavity, vagina or esophagus in patients with normal neutrophil count in the blood.

    With prolonged treatment, the likelihood of toxic effects increases.

    During the period of treatment, the patients are weighed, the general blood test, urine, the control of the potassium concentration in the blood, determine the functional state of the kidneys, liver, and ECG.Patients taking potassium preparations should regularly monitor the concentration of potassium and magnesium in the plasma.

    The administration of the drug to patients on hemodialysis is possible only after the completion of the dialysis procedure.

    All procedures with the solution should be carried out with. strict observance of aseptic rules, since the drug itself and all solutions intended for its dilution do not contain preservatives or bacteriostatic agents.

    When using intravenous systems previously established for other purposes, the system should be rinsed with 5% dextrose solution for injection. When anemia occurs, the drug should be discontinued.

    Form release / dosage:
    Lyophilizate for the preparation of a solution for infusions of 50,000 μg (ED) of the active substance.
    Packaging:

    In a vial of colorless glass with a capacity of 10 ml or 20 ml.

    1, 5 or 10 bottles with instructions for use are placed in a pack of cardboard. 50 bottles with 5 instructions for use are placed in a box of cardboard (for hospitals).

    Storage conditions:List B. In a dry, the dark place at a temperature of 2 to 10 ° C. Keep out of the reach of children.
    Shelf life:4 years.Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N003065 / 01
    Date of registration:14.05.2010
    Expiration Date:Unlimited
    The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.08.2017
    Illustrated instructions
      Instructions
      Up